PCSK9 Inhibitors and Neurocognitive Adverse Events: Exploring the FDA Directive and a Proposal for N-of-1 Trials

Overview of attention for article published in Drug Safety, May 2015

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (92nd percentile)
High Attention Score compared to outputs of the same age and source (93rd percentile)

Mentioned by

news: 2 news outlets
policy: 1 policy source

twitter: 8 X users
facebook: 1 Facebook page

Citations

dimensions_citation: 59 Dimensions

Readers on

mendeley: 82 Mendeley

Summary News Policy documents X Facebook Dimensions citations

So far, Altmetric has seen 1 policy document that references this research output.

Evolocumab

Cited by Canadian Agency for Drugs and Technologies in Health on 03 Dec 2018

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.